288. Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details

Clinical trials : 205 / Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00994929 (ClinicalTrials.gov)	January 2010	12/10/2009	Efficacy and Safety of IL-11 in DDAVP Unresponsive	Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP	Hemophilia A;Von Willebrand Disease	Biological: Neumega (Oprelvekin, Interleukin 11, IL-11)	University of Pittsburgh	NULL	Completed	18 Years	N/A	All	9	Phase 2	United States
2	NCT00524225 (ClinicalTrials.gov)	February 2008	31/8/2007	IL-11 in Adults With Von Willebrand Disease Undergoing Surgery	Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery	Von Willebrand Disease	Drug: Neumega (Oprelvekin, Interleukin 11, IL-11)	Margaret Ragni	University of North Carolina;Wyeth is now a wholly owned subsidiary of Pfizer	Terminated	18 Years	N/A	All	3	Phase 2	United States
3	NCT00524342 (ClinicalTrials.gov)	January 2008	31/8/2007	IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia	Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory Menorrhagia	Von Willebrand Disease	Drug: Oprelvekin , Interleukin 11, IL-11	Margaret Ragni	University of North Carolina;Wyeth is now a wholly owned subsidiary of Pfizer	Completed	18 Years	45 Years	Female	7	Phase 2	United States
4	NCT00151125 (ClinicalTrials.gov)	July 2004	6/9/2005	Phase II Study of IL-11 (Neumega) in Von Willebrand Disease	Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease	Von Willebrand Disease	Drug: recombinant interleukin-11	University of Pittsburgh	Wyeth is now a wholly owned subsidiary of Pfizer;University of North Carolina	Completed	18 Years	N/A	Both	12	Phase 2	United States